dc.creatorMartín Giménez, Virna Margarita
dc.creatorMocayar Maron, Feres Jose
dc.creatorGarcía, Sebastián
dc.creatorMazzei, Luciana Jorgelina
dc.creatorGuevara, Manuel Alejandro
dc.creatorYunes, Roberto Miguel Federico
dc.creatorManucha, Walter Ariel Fernando
dc.date.accessioned2022-05-09T15:25:30Z
dc.date.accessioned2022-10-15T00:40:39Z
dc.date.available2022-05-09T15:25:30Z
dc.date.available2022-10-15T00:40:39Z
dc.date.created2022-05-09T15:25:30Z
dc.date.issued2021-03
dc.identifierMartín Giménez, Virna Margarita; Mocayar Maron, Feres Jose; García, Sebastián; Mazzei, Luciana Jorgelina; Guevara, Manuel Alejandro; et al.; Central nervous system, peripheral and hemodynamic effects of nanoformulated anandamide in hypertension; Medical Univ Bialystok; Advances In Medical Sciences; 66; 1; 3-2021; 72-80
dc.identifier1896-1126
dc.identifierhttp://hdl.handle.net/11336/156928
dc.identifier1898-4002
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4325869
dc.description.abstractHypertensive lesions induce alterations at hemodynamic, peripheral, and central levels. Anandamide (N-arachidonoylethanolamine; AEA) protects neurons from inflammatory damage, but its free administration may cause central adverse effects. AEA controlled release by nanoformulations could reduce/eliminate its side effects. The present study aimed to evaluate the effects of nanoformulated AEA (nf-AEA) on systolic blood pressure (SBP), behavior, and central/peripheral inflammatory, oxidative, and apoptotic state in spontaneously hypertensive rats (SHR). Materials/methods: Male rats were used, both Wistar Kyoto (WKY) and SHR (n ​= ​10 per group), with/without treatment with nf-AEA (obtained by electrospraying) at a weekly dose of 5 ​mg/kg IP for 4 weeks. SBP was measured and behavioral tests were performed. Inflammatory/oxidative markers were quantified at the central (brain cortex) and peripheral (serum) level. Results: SHR showed hyperactivity, low anxiety, and high concentrations of central/peripheral inflammatory/oxidative markers, also higher apoptosis of brain cortical cells compared to WKY. As opposed to this group, treatment with nf-AEA in SHR significantly reduced SBP, peripheral/central inflammatory/oxidative makers, and central apoptosis. Nf-AEA also increased neuroprotective mechanisms mediated by intracellular heat shock protein 70 (Hsp70), which were attenuated in untreated SHR. Additionally, nf-AEA reversed the abnormal behaviors observed in SHR without producing central adverse effects. Conclusions: Our results suggest protective properties of nf-AEA, both peripherally and centrally, through a signaling pathway that would involve the type I angiotensin II receptor, Wilms tumor transcription factor 1, Hsp70, and iNOS. Considering non-nf-AEA limitations, this nanoformulation could contribute to the development of new antihypertensive and behavioral disorder treatments associated with neuroinflammation.
dc.languageeng
dc.publisherMedical Univ Bialystok
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S189611262030047X
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.advms.2020.12.003
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectANANDAMIDE
dc.subjectHYPERTENSION
dc.subjectINFLAMMATION
dc.subjectNANOFORMULATION
dc.subjectOXIDATIVE STRESS
dc.titleCentral nervous system, peripheral and hemodynamic effects of nanoformulated anandamide in hypertension
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución